Disclosure v. Coverage In Pharmaceutical Patents

The debate over disclosure versus claim coverage in pharmaceutical patents has long been a challenging one especially where a broad generic disclosure (e.g. via a Markush claim) attempts to cover potentially hundreds of millions of compounds on the strength of only a handful of working examples. Patents offer a trade-off: a time-limited monopoly to the innovator in exchange for full public disclosure of the invention so that, post-expiry, the knowledge enters the public domain.

In this context, inadequate disclosure jeopardises the patent's validity, while overly broad coverage leaves the door open for competitors to design around the patent. In pharmaceutical patents, this tension plays out most sharply because compounds are often claimed generically, but only a few representative compounds are synthesized, tested and disclosed with full data. The assumption - inherent to many Markush-style specifications - is that a "person skilled in the art" can, without